Leaders in Pharmaceutical Business Intelligence (LPBI) Group

PROTOCOL for Drug Screening of 3rd Party Intellectual Property Presented for Funding Representation

 

Author: Aviva Lev-Ari, PhD, RN

 

This PROTOCOL for LPBI Group’s Presentation of Intellectual Property  for Funding Sourcing comprises of two Investment Opportunity Types:

Type One:

3rd Party IP, i.e., Yossi/Yissum, Yedgar/Yissum, YEDA (Weitzman), T-cube (Technion)

• We will be on FINDER FEE AGREEMENTS with each party, same terms and conditions across all organizations

Type Two:

Investments in the Joint Venture: LPBI Group + SBH Sciences, Inc. or NewCo

• Investors assuming an Equity position

We @LPBI Group believe that, presentation of Funding Opportunities to Investors based on the below, described eleven steps process will demonstrate to the Investors the following Business advantages intrinsic to LPBI Group selection process of candidate Drugs for funding:

1. LPBI Group is an R&D outfit representing a Joint Venture with SBH Sciences, Inc. a US based profitable Biotech with $10Million in Sales that has reached out to GDE for its TEAM of MDs and PhDs to JOINTLY DEVELOP a pipeline of NCE.
2. LPBI Group is being approached by Third Parties for Funding in 1,2,3 Drug Indications
3. LPBI Group has an Eleven Steps Process for SCREENING drug candidates in which the TEAM and Dr. Nir are involved in decision making on what New Chemical Entities (NCE) to present to Investors, thus, shortening the Due Diligence to be done by the investors
4.  The Investors are given CHOICES to channel each DRUG DISCOVERY Project to a direct investor selected by them per “portfolio fit” and past interactions with given Drug Indications and Drug Classes we represent.

1,2,3,4 – will guarantee that our contacts in the Investment Community: NYC, Paris, Europe, Shanghai — will perceive GDE as a WHOLESALE channel with a robust pipeline of Drug Discovery Projects at hand.

 

The Process of Representation of a Third Party for purposes of Funding Sourcing involve the following steps:

1. The Third Party needs to identify Drug Discovery funding Target opportunities that belong to INDICATIONS 1,2,3, listed, below
2. These opportunities identified in 1, above, need to be presented to the Team by the Inventor over Skype per our PROCESS of decision making of inclusion for representation to our Investors, aka 

LPBI Group’s PROTOCOL for Drug Screening of 3rd Party Intellectual Property

We defined a process of ELEVEN steps. Our first cycle starts with Dr. Yedgar on 3/7/2016. He presented to the Team in November 2015, first time. This is his second presentation to the Team, 0n 3/8/2016.

Eleven STEPS in the WORKFLOW FOR FUNDING INVOLVEMENT of LPBI Group with Third Parties IP Owners

CASE STUDY: Explorations for funding with Biologics Inventor X

1. Aviva and Biologics Inventor Xwill meet on ______at 9AM EST, location TBA, optimal at Aviva’s place
2. GDE’s EAW(s) will arrive to to meet Biologics Inventor X
3. We will be on Skype for Biologics Inventor XPresentation to the Team from 9AM EST to 10:30AM EST: Mechanism of Actionand all US Patents with time stamp to expiration– Team will receive by e-mail the Presentation in attachment prior to Presentation
4. Team’s discussion of the Presentation 10:30AM EST to 11:30AM EST
5. Team’s session adjourn at 11:30AM EST
6. Biologics Inventor X, EAW(s) and Aviva will continue talking on the Commercialization potential and “How to go about that”

Vegetarian Lunch

Eaw(s) and Biologics Inventor X, Adjourn at 1:30PM EST

Biologics Inventor X and Aviva, adjourn at 2PM EST

 

Our Team activities related to 1 to 6, above – To FOLLOW:

7.   On ____9AM EST —Eaw(s), Gerard and Aviva will discuss our joint strategy on Skype regarding DRUG DISCOVERY on one or more of the following:

Diabetes

• Anti-inflamatory
• Anti-Cancer

as one candidate in the Pipeline of the Joint Venture [may comprise a proposal for three NCE], the other two in the Joint Venture pipeline are Diabetes [Stem cells and Combination drug therapy in Drug-Device] and Anti-Cancer [CAR-T and TCRL]

We will be preparing the

• Drug Discovery Plan,
• Drug Delivery Plan

for the Joint Venture or for NewCo to be presented by us to LPBI Groups Investment Partners.

8.  On ____ Team meeting at 10AM EST: Team will discuss of the Strategy presented by Gerard and Aviva, per discussions with Biologics Inventor X, third component by EAW(s) may be added

Team, please add the____, 9AM to 11:30AM to your Calendar. Please e-mail if you must be absent, otherwise, please attend and participate in the discussion following the Presentation

9.  Any additional parties, including Joint Venture Partners, please add the ____, 9AM to 1:30PM to your Calendar, visit to Aviva and in person meeting withBiologics Inventor X. Please Confirm your attendance by reply to ALL

Joint Venture Partners, please add ______9AM EST (Strategy discussion with Aviva and Gerard on Skype) and _______10AM EST (Team discussion of Strategy on Skype)

10.   Third Party IP representative will present to GDE Team, Drug Discoveries Candidates, and the Inventors, that the Representative wishes to present to our Team
11.  We will decide on inclusion. For example:

D.1   On Diabetes

D.1.1 ours

D.1.2 third party

D.2 On Anti-Inflammatory

D.2.1 ours

D.2.2 third party: Yedgar, Yossi and others

D.3  On Anti-Cancer: we will present to investors

D.3.1 our effort and

D.3.2 the opportunities at Woodland Pharmaceutical and X,Y,Z by third party, inventor and discovery

 

Summary

We @GDE believe that, THAT type of presentation to Investors demonstrate to them the following Business advantages:

1. GDE is an R&D outfit representing a Joint Venture with SBH Sciences, Inc. a US based profitable Biotech with $10Million in Sales that has reached out to GDE for its TEAM of MDs and PhDs to JOINTLY DEVELOP a pipeline of NCE.
2. GDE is being approached by Third Parties for Funding in 1,2,3 Drug Indications
3. GDE has an Eleven Steps Process for SCREENING drug candidates in which the TEAM and Dr. Nir are involved in decision making on what New Chemical Entities (NCE) to present to Investors, thus, shortening the Due Diligence to be done by the investors
4. The Investors are given CHOICES to channel each DRUG DISCOVERY Project to a direct investor selected by them per “portfolio fit” and past interactions with given Drug Indications and Drug Classes we represent.

1,2,3,4 – will guarantee that our contacts in the Investment Community: NYC, Paris, Europe, Shanghai — will perceive GDE as a WHOLESALE channel with a robust pipeline of Drug Discovery Projects at hand.

Funding will be awarded to:

Type One:

3rd Party IP, i.e., Yossi/Yissum, Yedgar/Yissum, YEDA (Weitzman), T-cube (Technion)

• We will be on FINDER FEE AGREEMENTS with each party, same terms and conditions

Type Two:

Investments in the Joint Venture:LPBI Group + SBH Sciences, Inc.

• Investors assuming an Equity position